Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Deep gene search aims to uncover why some young people get cancer

NCT ID NCT04141462

Knowledge-focused Sponsor: Centre Georges Francois Leclerc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at people who developed cancer at a young age (before 40, or before 30 for breast cancer) but had normal results on standard genetic tests. Researchers will use a more advanced technique called exome sequencing to search for new genetic changes that might raise cancer risk. The goal is to find hidden hereditary factors that current tests miss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could identify new genes linked to early-onset cancer, improving genetic testing and risk assessment for future patients.
What could go wrong
This is an observational study, not a treatment trial. It may not find new genes, and any discoveries would need further validation before helping patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 613 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2019

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Index case: 1. Major or minor patient 2. Histological or cytological evidence of malignant tumor diagnosis 3. Patient with cancer before age 40 (or before age 30 for breast cancer). 4. Absence of anomaly found on the oncogenetic panel tested in the predisposition concerned 5. Patient affiliated to a social security scheme 6. Signature of Informed Consent EXTRICAN 7. Availability of a tumor sample if needed secondary functional studies 8. Availability of both parents when the trio approach will be necessary in the population 1 (or validation of the indication in CPR in case of non-availability of both parents) 9. Availability of affected relatives in population 2 (or validation of the indication in SPC in case of non-availability of the related person) Related: 1. Major or minor patient 2. Histological or cytological evidence of the diagnosis of malignant tumor if 3. Patient affiliated to a social security scheme 4. Signing informed consent EXTRICAN Exclusion Criteria: Index and related case: 1. Refusal of the patient participation 2. Psychiatric illness and / or condition of the patient compromising the understanding of the information or the realization of the study 3. Patient under guardianship, curatorship or safeguard of justice 4. Pregnant woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer inherited disease susceptibility neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Genetic predisposition

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH de Troyes

    NOT_YET_RECRUITING

    Troyes, France

  • CHRU Jean Minjoz

    NOT_YET_RECRUITING

    Besançon, France

  • CHU de Dijon

    NOT_YET_RECRUITING

    Dijon, France

  • CHU de Reims

    NOT_YET_RECRUITING

    Reims, France

  • Centre Georges-François Leclerc

    RECRUITING

    Dijon, 21000, France

  • Polyclinique de Courlancy

    NOT_YET_RECRUITING

    Reims, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.